2 Furthermore, quantitative coronary angiography
|
|
- Owen Edwards
- 5 years ago
- Views:
Transcription
1 ORIGINAL PAPER Estimated Glomerular Filtration Rate Reversal by Blood Pressure Lowering in Chronic Kidney Disease: Japan Multicenter Investigation for Cardiovascular DiseaseB CKD Study Yoshiki Yui, MD; 1 Kazuhisa Kodama, MD; 2 Atsushi Hirayama, MD; 3 Saichi Hosoda, MD; 4 Chuichi Kawai, MD; 5 and the Japan Multicenter Investigation for Cardiovascular DiseaseB (JMIC-B) Study Group From the Kyoto University Hospital, Kyoto, Japan; 1 Amagasaki Central Hospital, Osaka, Japan; 2 Nihon University School of Medicine, Tokyo, Japan; 3 The Sakakibara Heart Institute, Tokyo, Japan; 4 and Takeda General Hospital, Kyoto, Japan 5 Patients are diagnosed as having chronic kidney disease (CKD) if estimated glomerular filtration rate () is <60 ml min 1.73 m 2. Low is likely to increase the incidence of cardiovascular events and lead to dialysis. Therefore, it is important to prevent from decreasing. However, it still remains unknown whether antihypertensive therapy can prevent low from becoming even lower and improve in hypertensive patients with CKD. The authors analyzed the results of the Japan Multicenter Investigation for Cardiovascular DiseaseB (JMIC-B) and investigated the effects of antihypertensive therapy on. In hypertensive patients with CKD ( <60), was significantly increased from (n=98) to (P<.001) after 3 years of antihypertensive therapy. In patients without CKD ( 60), was significantly decreased from (n=682) to (P<.001). Regardless of the type of antihypertensive drugs used, was significantly increased in patients with CKD and was significantly decreased in patients without CKD. This paper shows that antihypertensive therapy can improve in hypertensive patients with CKD. J Clin Hypertens (Greenwich). 2013; 15: Ó2012 Wiley Periodicals, Inc. The Japan Multicenter Investigation for Cardiovascular DiseaseB (JMIC-B) was a clinical study in which either nifedipine retard or an angiotensin-converting enzyme (ACE) inhibitor was administered for 3 years to hypertensive patients with coronary artery disease. As a result, there was no difference in the incidence of cardiac events between the two treatment groups, which suggests that strict control of blood pressure (BP) is more important than the class of drug used. 1 In hypertensive patients with diabetes (high-risk patients), there was also no significant difference in the incidence of cardiac events between the two treatments. 2 Furthermore, quantitative coronary angiography confirmed the preventive effect of nifedipine retard on arteriosclerosis. 3 Moreover, among hypertensive patients with a history of myocardial infarction, the incidence of angina pectoris requiring hospitalization was significantly lower in the nifedipine retard group than the ACE inhibitor group. 4 It was also found that reverse remodeling of the left ventricle and cardiac function can both be improved by decreasing BP. 5 Chronic kidney disease (CKD) is a well-known risk factor for cardiovascular events, and the estimated glomerular filtration rate () can be used as an index of CKD. 6 8 Address for correspondence: Yoshiki Yui, MD, Department of Cardiovascular Medicine, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto , Japan yoshiki@kuhp.kyoto-u.ac.jp Manuscript received: September 20, 2012; revised: October 22, 2012; accepted: October 26, 2012 DOI: /jch CKD can be diagnosed if is lower than 60 ml min 1.73 m 2. becomes lower with aging. For renal protection, it is important to prevent from becoming lower and improve low. We analyzed the results of JMIC-B and investigated whether antihypertensive therapy can improve low egrf in hypertensive patients with CKD. MATERIALS AND METHODS Hypertensive patients who were younger than 75 years and had coronary artery disease were registered to participate in JMIC-B. Among 1650 patients, 780 patients with data (0 and 36 months) were selected for this investigation. was obtained from 4 variables in the Modification of Diet in Renal Disease (MDRD) study equation. 9,10 BP was measured 3 times and the average of the last 2 readings was used. 1 Serum creatinine was assayed by the enzymatic method. We used estimated marginal means for comparison of (Figure 1). Estimated marginal means was obtained by a linear mixed effect model in which <60 or 60 and time was set as fixed effects, patients as a random effect, and propensity score as a covariate. Propensity score was calculated using a logistic regression model by setting <60 or 60 as a dependent variable, and sex, age, and use of diuretics and use of ACE inhibitors (baseline clinical characteristics) as independent variables. C statistics were Correction of P value for multiple pairwise comparison was done by Bonferroni correction. Propensity score was obtained using a logistic regression model by setting nifedipine or ACE Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension Vol 15 No 3 March
2 inhibitor as a dependent variable, and myocardial infarction, angina pectoris, hyperlipidemia, and antiplatelets as independent variables (Figures 3 and 4). C Statistics was Data were analyzed using IBM SPSS Statistics version 19 (BM Corp, Armonk, NY). Differences were regarded as significant at P<.05 (2-sided). Data are shown as meanstandard deviation. RESULTS The Table shows the baseline clinical characteristics of 780 patients according to whether they had CKD. There were significant differences in sex, age, serum creatinine and use of diuretics and ACE inhibitors. Figure 1 shows changes in during 3-year antihypertensive therapy in hypertensive patients with CKD and those without CKD: was significantly increased in those with CKD and was significantly decreased in those without CKD. Figure 2 shows the percentages of those whose was decreased and then increased after 3-year antihypertensive therapy according to baseline, which we stratified into 7 groups. The Cochrane-Armitage trend test was significant. The baseline and percentage of decrease or increase were significantly related. There was no statistical difference in systolic or diastolic BP among 7 groups. The effect of nifedipine and ACE inhibitors on is shown in Figures 3 and 4. With <60, was significantly improved, while with 60, was significantly decreased. There were no significant inter-drug differences. DISCUSSION CKD can be diagnosed if is <60 ml min 1.73 m 2. Relationships between CKD and cardiovascular diseases (CVDs) have been gaining attention: the risk of CVD increases with <60. Low is likely to lead to dialysis. It has been TABLE. Baseline Clinical Characteristics Number of Patients <60 (98 Patients) 60 (682 Patients) P Value Male female 52 (53.1) 46 (46.9) 483 (70.8) 199 (29.2) <.001 Age, y <.001 Coronary artery disease Myocardial infarction 44 (44.9) 285 (41.8).560 Angina pectoris 57 (58.2) 448 (65.7).145 Silent myocardial ischemia 10 (10.2) 77 (11.3).749 Complications Hyperlipidemia 27 (27.6) 168 (24.6).533 Diabetes mellitus 21 (21.4) 146 (21.4).996 Others 22 (22.4) 120 (17.6).244 History of smoking 26 (26.5) 229 (33.6).164 CAG (within past 1 y) 56 (57.1) 443 (65.0).132 PTCA (within past 1 y) 23 (23.5) 195 (28.6).291 Number of diseased vessels (AHA 75%) 1 vessel 31 (31.6) 255 (37.4) vessel 18 (18.4) 135 (19.8) vessel 5 (5.1) 46 (6.7).538 Left main trunk 0 (0) 3 (0.4) BP, mm Hg Systolic BP Diastolic BP Heart rate, per min Body mass index, kg m Serum creatinine, lmol L <.001 Serum cholesterol, mmol L Medications used before observation period Nitrates 70 (71.4) 448 (65.7).261 Diuretics 10 (10.2) 34 (5.0).036 b-blockers 20 (20.4) 138 (20.2).968 a-blockers 3 (3.1) 35 (5.1).613 Calcium channel blockers 47 (48.0) 336 (49.3).809 ACE inhibitors 21 (21.4) 94 (13.8).046 Antihyperlipidemic drugs 37 (37.8) 192 (28.2).051 Antiplatelets 58 (59.2) 368 (54.0).331 Abbreviations: ACE, angiotensin-converting enzyme; AHA, American Heart Association; BP, blood pressure; CAG, coronary angiography;, estimated glomerular filtration rate; PTCA, percutaneous transluminal coronary angioplasty. Statistics is the same as in Table I. 172 The Journal of Clinical Hypertension Vol 15 No 3 March 2013 Official Journal of the American Society of Hypertension, Inc.
3 * * **P= mL/min/1.73m 2 <60mL/min/1.73m 2 n=682 n=602 n=595 n=682 n=98 n=87 n=88 n=98 **P=0.197 **P=0.001 **P=0.005 *Welch s t-test FIGURE 1. The effects of 3-year antihypertensive therapy in patients with chronic kidney disease (CKD) and without CKD. FIGURE 2. The percentages of patients whose estimated glomerular filtration rate () was decreased and increased after 3-year antihypertensive therapy according to baseline (7 groups). DBP indicates diastolic blood pressure; SBP, systolic blood pressure. Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension Vol 15 No 3 March
4 <60 **P=0.007 **P=0.021 **P=0.845 Nifedipine ACE inhibitor n=44 n=54 n=38 n=49 n=39 n=44 n=49 n=54 **P=0.121 **P=0.002 **P=0.046 *Student t-test FIGURE 3. The effects of drugs on estimated glomerular filtration rate () in patients with chronic kidney disease (CKD). 60 **P=0.006 **P=0.034 **P=0.061 Nifedipine ACE inhibitor n=352 *P=0.538 n=311 *P=0.015 n=304 n=352 # P=0.752 # P=0.338 n=330 n=291 n=291 n=330 * **P=0.013 P**=0.018 #Student t-test *Welch s t-test FIGURE 4. The effects of drugs on estimated glomerular filtration rate () in patients without chronic kidney disease (CKD). reported that becomes lower with aging. These findings suggest that it is important to prevent from becoming lower or improve low. In recent years, relationships between lipids and CKD have been shown. It has also been investigated whether HMG-CoA reductase inhibitors can inhibit from becoming lower. 11,12 It is known that hypertension worsens renal function, but it remains unknown whether antihypertensive therapy can improve low. To resolve this question, we analyzed the results of JMIC-B. Of the 1650 patients in the study, 780 whose was measured at 0 and 36 months were used for the analysis (Table I). In hypertensive patients without CKD, 3-year antihypertensive therapy significantly decreased, while in those with CKD, it significantly increased (Fig- 174 The Journal of Clinical Hypertension Vol 15 No 3 March 2013 Official Journal of the American Society of Hypertension, Inc.
5 ure 1). The decrement in in patients without CKD (from to ml min 1.73m 2 ), while statistically significant, does not correlate with a clinically significant fall. Antihypertensive therapy does not worsen in patients without CKD. We also stratified baseline into 7 groups, instead of 2 groups ( <60 or 60) and investigated the percentage of patients whose was decreased and increased in each group. The Cochrane-Armitage trend test was significant: was decreased in a greater number of patients, with baseline being higher, while was increased in a greater number of patients, with baseline being lower (Figure 2). There were no significant differences in BP in any groups. In our study, nifedipine and ACE inhibitors were used. There were no significant differences in the improvement of according to the type of therapeutic drugs (Figures 3 and 4). However, the results might not be generalized to all classes of antihypertensive medications. Normal renal autoregulation enables the kidney to maintain a fairly constant renal blood flow and glomerular filtration rate as the mean arterial pressure varies between 80 mm Hg and 160 mm Hg. 13 Hypertension increases intraglomerular pressure and causes glomerular disorders. For the normalization of intraglomerular pressure, it is assumed to be necessary to decrease systemic BP. The results of our analysis support this assumption. The Irbesartan Diabetic Nephropathy Trial (IDNT) 14 and Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) 15 studies suggest that ACE inhibitors and ARBs are effective in inhibiting nephropathy from progressing. It has also been reported that calcium channel blockers also inhibit the progression of nephropathy in type II diabetes patients with hypertension, such as ACE inhibitors. 16 In 1989, a preliminary study by Pettinger and colleagues 17 suggested the potentiality for producing a significant improvement of renal function in hypertension-induced renal disease. In 2012, Hu and colleagues 18 reported that kidney function can improve in patients with hypertensive CKD. They showed that 31 of 949 patients demonstrated clearly positive slopes, which could not be explained by random measurement variation. STUDY LIMITATIONS There are limitations to our study. is associated with random measurement error, and the recovery of renal function might merely reflect regression to the mean. Small improvement in in patients with reduced and the slight deterioration in those with higher also might represent regression to the mean. Our study is not a placebo-controlled trial. CONCLUSIONS Large scale placebo-controlled trials of patients with low using various kinds of antihypertensive agents (angiotensin receptor blockers, ACE inhibitors, calcium channel blockers) are necessary. Disclosures: This study was partly supported by a grant-in-aid from the Positive Health Promotion Foundation. There is no conflict of interest. References 1. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res. 2004;27: Yui Y, Sumiyoshi T, Kodama K, et al. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res. 2004;27: Shinoda E, Yui Y, Kodama K, et al. Quantitative coronary angiogram analysis. Nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension. 2005;45: Yui Y, Shinoda E, Kodama K, et al. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive japanese patients with previous myocardial infarction (JMIC-B substudy). J Hypertens. 2007;25: Yui Y, Kodama K, Hirayama A, et al. Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease. J Hypertens. 2010;28: Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351: Solomon SD, Rice MM, A Jablonski K, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114: Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351: Levy AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145: Moe S, Druke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69: Shepherd J, Kastelein John JP, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to new Targets (TNT) Study. Clin J Am Soc Nephrol. 2007;2: Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular diseases in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54: Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347: Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losaltan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54: Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension. 1989;13: Hu B, Gadegbeku C, Lipkowitz MS, et al. Kidney function can improve in patients with hypertensive CKD. J Am Soc Nephrol. 2012;23: Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension Vol 15 No 3 March
ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationIncreased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects
ORIGINAL ARTICLE Increased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects Shu Meguro, Toshikatsu Shigihara, Yusuke Kabeya, Masuomi Tomita
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationAnalysis of Factors Causing Hyperkalemia
ORIGINAL ARTICLE Analysis of Factors Causing Hyperkalemia Kenmei Takaichi 1, Fumi Takemoto 1, Yoshifumi Ubara 1 and Yasumichi Mori 2 Abstract Objective Patients with impaired renal function or diabetes
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationAn acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
original article http://www.kidney-international.org & 2011 International Society of Nephrology see commentary on page 235 An acute fall in estimated glomerular filtration rate during treatment with losartan
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationHypertension is an important global public
IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual
More informationSupplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationTHE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS
214 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(3):23-212 doi: 1.2478/rjdnmd-214-25 THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES
More informationKDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease
KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease February 5-8, 2015 Vancouver, Canada Kidney Disease: Improving Global Outcomes (KDIGO) is an international
More informationClassification of CKD by Diagnosis
Classification of CKD by Diagnosis Diabetic Kidney Disease Glomerular diseases (autoimmune diseases, systemic infections, drugs, neoplasia) Vascular diseases (renal artery disease, hypertension, microangiopathy)
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationEffects of Lowering LDL Cholesterol on Progression of Kidney Disease
Effects of Lowering LDL Cholesterol on Progression of Kidney Disease Richard Haynes, David Lewis, Jonathan Emberson, Christina Reith, Lawrence Agodoa, Alan Cass, Jonathan C. Craig, Dick de Zeeuw, Bo Feldt-Rasmussen,
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationFerrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular mortality in hypertension: a meta-analysis of randomized controlled trials Ferrari R, Fox K, Bertrand
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationManagement of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Review Advances in CKD 216 Published online: January 15, 216 Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Hillel Sternlicht George L. Bakris Department of Medicine, Section
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationKDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease
KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease February 5-8, 2015 Vancouver, Canada Kidney Disease: Improving Global Outcomes (KDIGO) is an international
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationRenal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationLow-Dose Candesartan Cilexetil Prevents Early Kidney Damage in Type 2 Diabetic Patients with Mildly Elevated Blood Pressure
453 Original Article Low-Dose Candesartan Cilexetil Prevents Early Kidney Damage in Type 2 Diabetic Patients with Mildly Elevated Blood Pressure Satoru MURAYAMA, Tsutomu HIRANO, Taro SAKAUE, Kenta OKADA,
More informationBlood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial
Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Kenji Ueshima 1, Shinji Yasuno 1, Sachiko Tanaka 1, Akira Fujimoto 1, Toshio Ogihara 2, Takao
More informationSupplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures
Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationEffects of statin therapy on chronic kidney disease patients with coronary artery disease
Shen et al. Lipids in Health and Disease (2018) 17:84 https://doi.org/10.1186/s12944-018-0742-4 RESEARCH Open Access Effects of statin therapy on chronic kidney disease patients with coronary artery disease
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationCharacteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study
ORIGINAL PAPER Characteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study Yi Zhang, MD, PhD; 1 Helene Lelong, MD; 2 Sandrine
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationFan Shunan 1, Yuan Jiqing 2 and Dong Xue 3. Introduction. Original Article
803495JRA0010.1177/1470320318803495Journal of the Renin Angiotensin Aldosterone SystemShunan et al. research-article20182018 Original Article Effects of angiotensin-converting enzyme inhibitors and angiotensin
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES
Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression
More informationChronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
More informationUsefulness of a large automated health records database in pharmacoepidemiology
Environ Health Prev Med (2011) 16:313 319 DOI 10.1007/s12199-010-0201-y REGULAR ARTICLE Usefulness of a large automated health records database in pharmacoepidemiology Hirokuni Hashikata Kouji H. Harada
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationCaring for Australians with Renal Impairment. BP lowering and CVD
Caring for Australians with Renal Impairment BP lowering and CVD Questions: Conflicts of Interest: RH, TN, HHL- no conflict VP- level II conflict Speakers fees: Abbott, Astra Zeneca, Roche, Servier Grant
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationHypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA
Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of
More informationLife After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention
Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis
More informationDiabetes is the most common cause of end-stage renal
Pharmacoeconomic Challenges in the Management of Diabetic Nephropathy ROGER A. RODBY, MD ABSTRACT BACKGROUND: Diabetes is the most common cause of end-stage renal disease (ESRD) kidney failure to the point
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationRETARDING PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)
13 : 6 RETARDING PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD) Abstract: Chronic Kidney Disease (CKD) is common, harmful and treatable. It is worldwide public health problem, with several adverse outcomes;
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationC URRENT T HERAPEUTIC R ESEARCH. 94 Copyright 2007 Excerpta Medica, Inc. Reproduction in whole or part is not permitted.
C URRENT T HERAPEUTIC R ESEARCH V OLUME 68, NUMBER 2, MARCH/APRIL 27 Anti-Albuminuric Effect of Losartan Versus Amlodipine in Hypertensive Japanese Patients with Type 2 Diabetes Mellitus: A Prospective,
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationTarget Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD
Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More information